Lexaria Bioscience Corp. LEXX Archives - Page 33 of 39

TuesdayDec 14, 2021 1:25 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week. The study, undertaken to examine the effects of DehydraTECH-CBD upon acute pulmonary hypertension, used a blinded design with administration of a single 300mg dose of a specific DehydraTECH 2.0 CBD formulation compared to placebo in a target group of sixteen enrolled volunteers. Subject to pending analysis of samples collected from the study, blood pressure results are expected to be reported soon. Exposure to acute reductions in oxygen tension (i.e.,…

TuesdayDec 14, 2021 12:54 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life

Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it Going into 2022, the company looks forward to reporting on results from its HYPER-H21-3 clinical study and receiving Independent Review Board (“IRB”) approval for its HYPER-H21-4 study Lexaria Bioscience (NASDAQ: LEXX) just participated in this year’s Benzinga Global Small Cap Conference. The two-day event was a showcase for small cap…

FridayDec 10, 2021 10:20 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion

Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success…

WednesdayDec 08, 2021 12:27 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics

Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeability Lexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstream DehydraTECH achieves this by bypassing first-pass-liver metabolism By doing so, Lexaria is facilitating faster and much more thorough drug delivery In a report published in the Bioavailability Enhancement Technologies and Services Market, 2018-2030, it was established that around 40% of available marketed drugs are poorly bioavailable or soluble. It was further estimated that approximately 90% of New…

WednesdayDec 08, 2021 11:53 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional results from its human clinical study HYPER-H21-2. The study was designed to evaluate the company’s proprietary DehydraTECH(TM)-processed cannabidiol ("CBD") and its effectiveness in the treatment of hypertension. Results confirm the substance’s ability to reduce arterial stiffness and indicate potential broader applications beyond hypertension, including the treatment of cardiovascular and other diseases. According to the company, arterial stiffness can be a predictor of a variety of human diseases, including hypertension, diabetes mellitus, renal disease and more. A unique CBD formulation developed by Lexaria, DehydraTECH-CBD is based on the…

TuesdayDec 07, 2021 11:20 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that it is participating in the Benzinga Global Small Cap Conference. The premier two-day virtual event is scheduled for Dec. 8–9, 2021. The company encourages shareholders and other interested parties to attend the event and learn more about investment opportunities within the global small cap space. The conference is designed to bridges the gap between small cap companies, investors and traders. The event provides an ideal environment to learn about small cap investing. The conference agenda features insightful educational modules and provides a clear look at a curated…

ThursdayDec 02, 2021 12:38 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which…

WednesdayNov 24, 2021 12:35 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over the course of two hours. “The results from the study showed that the generic nicotine benzoate pouch required about 45 minutes to reach its peak delivery rate. In comparison, the DehydraTECH-nicotine benzoate pouch reached peak delivery rates at both eight minutes and again at 30…

WednesdayNov 24, 2021 8:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications

Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension HYPER-H21-4 will build on successes witnessed in initial human hypertension studies The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid disease Lexaria is committed to improving lives and lessening deaths through its patented DehydraTECH(TM) technology With a fully-funded research and development (“R&D”) budget, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed, efficacy, bioavailability, and brain absorption of…

ThursdayNov 18, 2021 8:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes

Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery platform Lexaria will also be conducting pharmacokinetic and efficacy modeling studies in animals to evaluate DehydraTECH’s overall efficiency In 2021, Lexaria Bioscience (NASDAQ: LEXX) raised approximately $15 million in funding. The money allowed for active work programs throughout the year while supporting significant advances in…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX